ACADIA (ACAD) Q2 FY26 earnings call

ACADIA delivered a strong second quarter, driven by robust commercial execution for both DAYBUE and NUPLAZID, leading to an upward revision of DAYBUE's full-year guidance. The company is advancing its pipeline, with the highly anticipated Phase II readout for remlifanserin in Alzheimer's disease psychosis expected in September to October, and preparations underway for DAYBUE's European launch.